Status:
COMPLETED
Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study
Lead Sponsor:
Fudan University
Conditions:
Colorectal Cancer
Refractory Colorectal Cancer
Eligibility:
All Genders
Brief Summary
Fruquintinib is an oral tyrosine kinase inhibitor (TKI), which improves progression-free survival (PFS) and overall survival (OS) in patients with refractory metastatic colorectal cancer (mCRC). Here,...
Eligibility Criteria
Inclusion
- (1) histology-confirmed metastatic CRC (mCRC); (2) disease progression on standard therapy with at least two lines of chemotherapy, including fluorouracil, oxaliplatin, and irinotecan with or without biologics such as bevacizumab and cetuximab; (3) fruquintinib administered as salvage treatment; (4) available clinical data.
Exclusion
- (1) lack of follow-up data; (2) fruquintinib administration as second-line treatment; (3) fruquintinib administration stopped after less than two cycles.
Key Trial Info
Start Date :
January 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 25 2023
Estimated Enrollment :
520 Patients enrolled
Trial Details
Trial ID
NCT06202417
Start Date
January 1 2021
End Date
December 25 2023
Last Update
January 11 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China, 200032